MedTrace Logo

Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

NCT01861197 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2013-05-23

No results posted yet for this study

Summary

Efficacy of Dovitinib for Squamous NSCLC.

Conditions

  • Squamous NSCLC

Interventions

DRUG

Dovitinib

Dovitinib 500mg daily for 5 days on/ 2 day off until progression

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Myung-Ju Ahn · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01861197 on ClinicalTrials.gov